A Possible Role of CD46 for the Protection In Vivo of Human Renal Tumor Cells from Complement-Mediated Damage
- 1 March 2000
- journal article
- Published by Elsevier in Laboratory Investigation
- Vol. 80 (3) , 335-344
- https://doi.org/10.1038/labinvest.3780038
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Control of C3b and C5b deposition by CD46 (membrane cofactor protein) after alternative but not classical complement activationEuropean Journal of Immunology, 1999
- Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related componentsEuropean Journal Of Cancer, 1998
- Phase II Trial of Interleukin-2 and Interferon-ce in Patients with Renal Cell Carcinoma: Clinical Results and Immunologic Correlates of ResponseJournal of Immunotherapy, 1997
- The role of immunotherapy for urological tumoursBritish Journal of Urology, 1997
- Augmented Lung Adenocarcinoma Cytotoxicity by the Combination of a Genetically Modified Anti‐Lewis Y Antibody and Antibodies to Complement Regulatory ProteinsScandinavian Journal of Immunology, 1995
- Expression of protectin (CD59) in human melanoma and its functional role in cell‐ and complement‐mediated cytotoxicityInternational Journal of Cancer, 1995
- Identification and characterization of membrane cofactor protein (CD46) in the human kidneysEuropean Journal of Immunology, 1994
- The management of renal cell carcinomaCritical Reviews in Oncology/Hematology, 1994
- Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro.Journal of Clinical Investigation, 1988
- Monoclonal antibody G 250 recognizes a determinant present in renal‐cell carcinoma and absent from normal kidneyInternational Journal of Cancer, 1986